Results 141 to 150 of about 57,705 (278)

Mapping molluscan endocrinology: a systematic and critical appraisal

Biological Reviews, Volume 101, Issue 2, Page 970-1002, April 2026.
ABSTRACT Historically, a vertebrate‐centric paradigm has framed our interpretation of molluscan endocrinology, with considerable research focusing on vertebrate‐type steroid hormones (e.g. oestrogens, testosterone). However, contradictory evidence on the occurrence of vertebrate‐type steroid hormones in molluscan tissues, and a lack of the specific ...
Konstantinos Panagiotidis, Thomas H. Miller, Olwenn V. Martin, Alice Baynes   +3 more
wiley   +1 more source

Computational drug designing of fungal pigments as potential aromatase inhibitors

Bangladesh Journal of Pharmacology, 2014
The existing aromatase inhibitors produced unwelcome effects impose the discovery of novel drugs with privileged selectivity, a reduced amount of toxicity and humanizing potency.
Nighat Fatima, Abida Kalsoom, Amara Mumtaz, Syed Aun Muhammad   +3 more
doaj  

Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer

, 2017
Holm Eggemann, U Altmann, Serban‐Dan Costa, Atanas Ignatov   +3 more
openalex   +2 more sources

Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model [PDF]

, 1998
Ronald A. Lubet
openalex   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Impact of endocrine therapy regimens for early-stage ER+/HER2- breast cancer on contralateral breast cancer risk

npj Breast Cancer
Endocrine therapy for breast cancer may reduce the risk of contralateral breast cancer (CBC). However, there are no published estimates quantifying the lifetime outcomes by age at primary diagnosis, regimen, or duration.
Swarnavo Sarkar, Clyde Schechter, Allison W. Kurian, Jennifer L. Caswell-Jin, Jinani Jayasekera, Jeanne S. Mandelblatt   +5 more
doaj   +1 more source

Reprogramming SREBP1‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention

International Journal of Cancer, Volume 158, Issue 7, Page 1927-1940, 1 April 2026.
What's new? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan, Elizabeth T. Bartom, Carolina H. Chung, Xingyu Guo, Kyli Berkley, Seyyedmohsen Hosseinibarkooie, Zahra Assadi, Shao Huan Samuel Weng, Raymond Moellering, Oukseub Lee, Ruohui Chen, Wonhwa Cho, Sriram Chandrasekaran, Susan E. Clare, Seema A. Khan   +14 more
wiley   +1 more source

Laser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial

International Journal of Gynecology &Obstetrics, Volume 173, Issue 1, Page 99-108, April 2026.
Abstract Background Breast cancer survivors (BCS) often experience more severe symptoms of genitourinary syndrome of menopause (GSM). As estrogen‐based hormonal therapy is generally avoided in BCS, physical energy methods may offer promising non‐hormonal alternatives.
Nicoli Serquiz, Ayane Cristine Alves Sarmento, Antonio Carlos Queiroz de Aquino, Natalie Rios Almeida, Maria Luísa Nobre, Juliana Dantas de Araújo Santos Camargo, Kleyton Santos de Medeiros, Ana Katherine Gonçalves   +7 more
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Adherence challenges in breast cancer: Evaluating tamoxifen and aromatase inhibitors in adjuvant hormone therapy [PDF]

Natalia Camejo, Dahiana Amarillo, Cecilia Castillo, Lucía Argenzio, Djalma Pereira Santana, Guadalupe Herrera, Luis Felipe Cabrera, María Guerrina, Carolina Dörner, Gabriel Krygier   +9 more
openalex   +1 more source